icon- folder.gif   Conference Reports for NATAP  
 
  XVII International AIDS Conference
Mexico City
3-8 August 2008
Back grey_arrow_rt.gif
 
 
 
Metabolic Outcomes from Prospective, Randomized Clinical Trials of Tenofovir DF (TDF) Compared to Thymidine Analog-containing Efavirenz-based Regimens in Antiretroviral-Naive Patients
 
 
  Reported by Jules Levin
IAC Mexico City Aug 3-8 2008
 
RE Campo,1 JE Gallant,2 AL Pozniak,3 E DeJesus,4 Y Zhou,5 AK Cheng,5 and J Enejosa5. 1Univ Miami, Miami, FL; 2Johns Hopkins Univ School of Medicine, Baltimore, MD; 3Chelsea & Westminster Hosp, London, UK; 4Orlando Immunology Center, Orlando, FL; 5Gilead Sciences, Foster City, CA
 
AUTHOR CONCLUSIONS
 
Significantly smaller increases in fasting total cholesterol, LDL-C and triglycerides were seen with TDF-containing vs. thymidine analog-containing EFV-based regimens through 144 wks
 
Higher proportion of patients in thymidine analog group added lipid-lowering agent compared to TDF
 
Higher proportion of patients on TDF remained within NCEP ATP III guidelines for lipid level goals
 
Median limb fat was higher in the TDF group compared to the thymidine analog group
 
Treatment with a thymidine analog was associated with ≥ 20% decrease in limb fat from Wk 96 to Wk 144
 
BACKGROUND
 
Metabolic abnormalities have been observed in HIV patients receiving highly active antiretroviral therapy:
--Hypercholesterolemia with or without hypertriglyceridemia
--Morphological changes: limb fat wasting and central fat accumulation
--Drugs within each antiretroviral class have different effects on lipids and fat distribution
--ACTG 5142 demonstrated a lower incidence of lipoatrophy among patients who received efavirenz (EFV)+ lopinavir/ritonavir (LPV/r) or LPV/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared to EFV+2 NRTIs
--Lipoatrophy in the EFV or LPV/r +NRTI arms was predominantly seen in the stavudine (d4T) or zidovudine (ZDV)-containing regimens

design-1.gif

METHODS
 
We evaluated changes in limb fat (by DEXA) and fasting lipids in patients who initiated a TDF-containing vs. a thymidine analog-containing regimen (Control) in Studies 903 and 934
 
DEXA was performed at Wks 96 and 144, and lipids were obtained at baseline (BL) and every 12 weeks
 
Logistic regression analysis was performed to assess factors potentially associated with a decrease in limb fat of ≥20% from Week 96 to Week 144
 
Main Inclusion Criteria:
--HIV-1 infected patients naive to antiretroviral treatment
--18-65 years of age
--Plasma HIV RNA > 5,000 copies/mL (Study 903); >10,000 copies/mL (Study 934)
--No CD4+ cell count criteria
--No significant laboratory or clinical abnormalities
 
RESULTS
 

table-2.gif

agent-3.gif

limb-4.gif

TDF-5.gif

Logistic regression analysis was performed to evaluate factors associated with ≥ 20% decrease in limb fat from Wk 96 to Wk 144
--Factors assessed: baseline age, sex, race, weight, HIV-1 RNA, CD4, fasting lipid values and treatment group
 
In a multivariate analysis, only treatment with thymidine analogs was associated with ≥ 20% decrease in limb fat from Wk 96 to Wk 144